Chuang Yi Biotech Valuation
Is 6566 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6566 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6566's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6566's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6566?
Key metric: As 6566 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 6566's PS Ratio? | |
|---|---|
| PS Ratio | 0.7x |
| Sales | NT$252.41m |
| Market Cap | NT$176.47m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.6x |
| Enterprise Value/EBITDA | -7.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6566's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 15.2x | ||
6935 Prince Pharmaceutical | 1.1x | n/a | NT$803.5m |
4192 SynCore BiotechnologyLtd | 55x | n/a | NT$1.3b |
4102 Yung Zip Chemical Ind | 2.2x | n/a | NT$1.4b |
6817 Winston Medical Supply | 2.3x | n/a | NT$1.6b |
6566 Chuang Yi Biotech | 0.7x | n/a | NT$176.5m |
Price-To-Sales vs Peers: 6566 is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (1.7x).
Price to Sales Ratio vs Industry
How does 6566's PS Ratio compare vs other companies in the TW Pharmaceuticals Industry?
| 12 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 4.9x | 73.3% | |
6566 Chuang Yi Biotech | 0.7x | n/a | US$5.49m |
3705 YungShin Global Holding | 1.9x | n/a | US$461.38m |
1720 Standard Chemical & Pharmaceutical | 1.7x | n/a | US$351.86m |
| 12 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 4.9x | 61.8% | |
6566 Chuang Yi Biotech | 0.7x | n/a | US$5.49m |
Price-To-Sales vs Industry: 6566 is good value based on its Price-To-Sales Ratio (0.7x) compared to the TW Pharmaceuticals industry average (5.3x).
Price to Sales Ratio vs Fair Ratio
What is 6566's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6566's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
RBC Bioscience
NT$253.0m
Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.
6848
NT$19.50
7D
-0.3%
1Y
20.4%
TSH Biopharm
NT$2.5b
Develops and markets pharmaceutical products in Taiwan and Asia.
8432
NT$65.00
7D
1.9%
1Y
27.2%
Winston Medical Supply
NT$1.6b
Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.
6817
NT$89.00
7D
0.3%
1Y
-18.3%